Trevor Aldred
Family Medicine · Lewes, DENPI 1639705650
Payments from drug & device makers
Across 85 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$312
- AstraZeneca$259
- Exact Sciences$210
- Lilly USA, LLC$161
- Abbott$118
- Pfizer$95
- plus $534 from 14 others
What the payments were for
- Food & beverage$1,689100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $312 |
| AstraZeneca | 15 | $259 |
| Exact Sciences | 9 | $210 |
| Lilly USA, LLC | 8 | $161 |
| Abbott | 5 | $118 |
| Pfizer | 5 | $95 |
| Merck | 3 | $80 |
| Amgen | 4 | $67 |
| Boehringer Ingelheim | 4 | $61 |
| Irhythm Technologies, Inc. | 1 | $55 |
| Dexcom, Inc. | 2 | $39 |
| Bayer | 2 | $39 |
| Tactile Systems Technology Inc | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Biogen | 1 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| GSK | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$1,689 in reported general payments places this provider in the 75th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $113,648 |
| JardianceEmpagliflozin | 51 | $78,391 |
| EliquisApixaban | 36 | $52,724 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $35,430 |
| TrulicityDulaglutide | 18 | $31,704 |
| RybelsusSemaglutide | 12 | $22,990 |
| FarxigaDapagliflozin Propanediol | 11 | $17,635 |
| MounjaroTirzepatide | 17 | $16,947 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,174 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $11,384 |
| MyrbetriqMirabegron | 12 | $10,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $10,294 |
| Atorvastatin Calcium | 715 | $9,145 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,536 |
| LinzessLinaclotide | 11 | $6,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $312 | $136,63871 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $61 | $85,92763 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $18 | $58,89862 claims |
| PfizerEliquis | $95 | $52,72436 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $161 | $48,65135 claims |
| AstraZenecaFarxiga, Symbicort | $259 | $23,09734 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $10,36912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 352 family medicine providers in Delaware.
Other family medicine in Lewes
- Catherine de LucaLewes$6K
- David KrasnerWilmington$110K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- David BirchMilford$24K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.